Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Mayo Clinic

Sites in Rochester, MN

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 2:02 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1826
Shown on this page
12
Current sort
Recently updated
Campus scope
Mayo Clinic, Rochester, MN
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Mayo Clinic, Rochester, MN. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 1009–1020 of 1,826 matching trials with a site at Mayo Clinic, Rochester, MN.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Recruiting Phase 2 Interventional

DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers

NCT05882058
Status at this site: Recruiting
View directory record Official record
Conditions
Small Cell Lung Carcinoma, Neuroendocrine Neoplasms, Extra-pulmonary Neuroendocrine Carcinoma
Interventions
BI 764532, dose 1, BI 764532, dose 2, Ventana DLL3 RxDx assay
Drug · Device
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
16
States / cities
Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Nov 3, 2026, 2:02 PM EST
Recruiting Not applicable Interventional

COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction

NCT02744677
Status at this site: Recruiting
View directory record Official record
Conditions
Complex Congenital Heart Defect, Dysfunctional RVOT Conduit, Pulmonary Valve Insufficiency, Pulmonary Valve Degeneration
Interventions
SAPIEN 3/SAPIEN 3 Ultra RESILIA THV, SAPIEN 3 THV, SAPIEN 3 Ultra RESILIA THV
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
Not listed
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2031
U.S. locations
27
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Nov 3, 2026, 2:02 PM EST
Active, not recruiting Not applicable Interventional Results available

Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation

NCT03433274
Site status not listed — check the official record
View directory record Official record
Conditions
Mitral Regurgitation, Mitral Insufficiency, Mitral Valve Insufficiency, Cardiovascular Diseases, Valve Disease, Heart, Heart Valve Diseases, Functional Mitral Regurgitation, Degenerative Mitral Valve Disease
Interventions
Tendyne Mitral Valve System, MitraClip System
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
73
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Nov 3, 2026, 2:02 PM EST
Recruiting Not applicable Interventional

MRI-guided Transurethral Urethral Ultrasound Ablation for the Treatment of Low to Intermediate Grade Prostate Cancer

NCT05438563
Status at this site: Recruiting
View directory record Official record
Conditions
Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8
Interventions
MRI-Guided Transurethral Ultrasound Ablation, Questionnaire Administration, Digital Rectal Examination, Cystoscopy, Biopsy, Bone Scan, PSMA PET Scan, Multiparametric Magnetic Resonance Imaging
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
45 Years to 80 Years · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Nov 3, 2026, 2:02 PM EST
Active, not recruiting Phase 1Phase 2 Interventional

Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations

NCT05256290
Site status not listed — check the official record
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Cancer, NSCLC, Advanced Lung Carcinoma, Epidermal Growth Factor Receptor C797S, Epidermal Growth Factor Receptor G719X, EGF-R Positive Non-Small Cell Lung Cancer, EGFR-TKI Resistant Mutation
Interventions
silevertinib (BDTX-1535) monotherapy
Drug
Lead sponsor
Black Diamond Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
25
States / cities
Birmingham, Alabama • Gilbert, Arizona • Huntington Beach, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Nov 3, 2026, 2:02 PM EST
Recruiting No phase listed Observational

Rare Kidney Stone Consortium Biobank

NCT02026388
Status at this site: Recruiting
View directory record Official record
Conditions
Primary Hyperoxaluria, Dent Disease, APRT Deficiency, Cystinuria
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
Not listed
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2030
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Nov 3, 2026, 2:02 PM EST
Active, not recruiting Phase 1 Interventional

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

NCT04521686
Site status not listed — check the official record
View directory record Official record
Conditions
Cholangiocarcinoma, Chondrosarcoma, Glioma, Any Solid Tumor
Interventions
LY3410738, Gemcitabine, Cisplatin, Durvalumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
17
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Nov 3, 2026, 2:02 PM EST
Active, not recruiting Phase 2 Interventional

Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors

NCT03485209
Site status not listed — check the official record
View directory record Official record
Conditions
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer, Carcinoma, Squamous Cell of Head and Neck
Interventions
tisotumab vedotin, pembrolizumab, carboplatin, cisplatin
Drug
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
124
States / cities
Encinitas, California • La Jolla, California • Sacramento, California + 57 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Nov 3, 2026, 2:02 PM EST
Recruiting Not applicable Interventional

Evaluation of A Clinical Diagnostic Test for CRDS

NCT06188689
Status at this site: Recruiting
View directory record Official record
Conditions
Calcium Release Deficiency Syndrome (CRDS)
Interventions
Pacing
Diagnostic Test
Lead sponsor
Population Health Research Institute
Other
Eligibility
Not listed
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
4
States / cities
San Francisco, California • Boston, Massachusetts • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Nov 3, 2026, 2:02 PM EST
Recruiting Phase 3 Interventional

A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

NCT05253651
Status at this site: Recruiting
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
tucatinib, trastuzumab, bevacizumab, cetuximab, oxaliplatin, leucovorin, levoleucovorin, fluorouracil
Drug
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
132
States / cities
Glendale, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 82 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Nov 3, 2026, 2:02 PM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

A Study of TopSpin360 Training Device

NCT06052553
Status at this site: Recruiting
View directory record Official record
Conditions
Healthy
Interventions
TopSpin360
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 21 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Nov 3, 2026, 2:02 PM EST
Active, not recruiting Phase 3 Interventional

Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)

NCT07003919
Site status not listed — check the official record
View directory record Official record
Conditions
Allergy, Peanut Allergy
Interventions
DBV712 250 mcg, Placebo
Combination Product
Lead sponsor
DBV Technologies
Industry
Eligibility
1 Year to 3 Years
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
56
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Nov 3, 2026, 2:02 PM EST

About this Mayo Clinic institution page

What this page lists
ClinicalTrials.gov records that list Mayo Clinic in Rochester, MN as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by Mayo Clinic at any site, browse by condition, or browse by U.S. city.